Clinical trials
Fallopian Tube Neoplasms trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
85 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 3 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 5 |
| 2011 | 5 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 7 |
| 2017 | 3 |
| 2018 | 6 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 6 |
| 2023 | 5 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 40 |
| Active, not recruiting | 18 |
| Terminated | 11 |
| Recruiting | 10 |
| Unknown status | 5 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 13 |
| University Health Network, Toronto | 9 |
| pharmaand GmbH | 6 |
| AbbVie | 4 |
| Amgen | 3 |
| ImmunoVaccine Technologies, Inc. (IMV Inc.) | 3 |
| Merck Sharp & Dohme LLC | 3 |
| NCIC Clinical Trials Group | 3 |
| AltaRex | 2 |
| AstraZeneca | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fallopian Tube Neoplasms | 85 |
| Ovarian Neoplasms | 67 |
| Carcinoma, Ovarian Epithelial | 39 |
| Neoplasms | 11 |
| Peritoneal Neoplasms | 9 |
| Recurrence | 9 |
| Endometrial Neoplasms | 6 |
| Triple Negative Breast Neoplasms | 5 |
| Breast Neoplasms | 4 |
| Brenner Tumor | 4 |
Trials
Showing 51 to 75 of 85. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.